Rentosertib, an AI-designed compound targeting TNIK, produced measurable reductions in proteomic aging clocks across six independent aging biomarkers in a 12-week Phase IIa trial of 42 idiopathic pulmonary fibrosis patients. The dose-dependent improvement in forced vital capacity aligned with proteomic findings, demonstrating concordance between molecular aging markers and clinical pulmonary function.
Key Points
- Six proteomic aging clocks showed biological age reversal in treated patients
- Dose-dependent forced vital capacity improvement paralleled proteomic clock findings
- TNIK inhibition targets six recognized hallmarks of aging simultaneously
Longevity Analysis
The integration of proteomic aging clocks into a Phase IIa clinical trial establishes a template for measuring systemic aging reversal through protein signatures rather than waiting for traditional outcome measures. This approach recognizes that tissue degeneration and proteostatic collapse drive multiple pathological states, and that restoring protein homeostasis can decelerate aging across distinct organ systems. The alignment between molecular aging markers and pulmonary function suggests that targeting a single node in the aging network—in this case, a gene implicated in six aging hallmarks—may produce coordinated reversal across multiple physiological domains. Success at this stage indicates that aging itself, not merely age-related disease, may be modifiable through precision pharmacology.
Original published by LT Wire.